Table 3 Univariate analysis of prognostic factors
Characteristic | LFFS | DMFS | OS | |||
|---|---|---|---|---|---|---|
HR(95%CI) | P value | HR(95%CI) | P value | HR(95%CI) | P value | |
Gender(Male/Female) | 0.44 (0.123–1.582) | 0.209 | 0.441 (0.201–0.966) | 0.041 | 0.540 (0.231–1.265) | 0.156 |
Age(y) | 0.996 (0.947–1.047) | 0.872 | 1.021 (0.990–1.053) | 0.193 | 1.013 (0.978–1.013) | 0.464 |
Pathology (Type II/III) | 0.873 (0.114–6.687) | 0.896 | 1.489 (0.526–4.213) | 0.453 | 2.471 (0.941–6.485) | 0.066 |
GTV Dose (Gy) | 0.998 (0.990–1.006) | 0.635 | 1.004 (1.000–1.007) | 0.026 | 1.003 (1.000–1.007) | 0.086 |
T stage(T1/T2/T3/T4) | 0.923 (0.561–1.520) | 0.754 | 1.250 (0.905–1.727) | 0.176 | 1.472 (1.000–2.166) | 0.050 |
NeoCT (cycles) | 0.982 (0.524–1.840) | 0.954 | 0.716 (0.457–1.121) | 0.144 | 0.598 (0.337–1.060) | 0.078 |
ConCT (cycles) | 0.961 (0.509–1.817) | 0.904 | 1.037 (0.698–1.541) | 0.856 | 1.071 (0.681–1.683) | 0.767 |
AdjCT (cycles) | 0.937 (0.469–1.870) | 0.853 | 0.983 (0.647–1.494) | 0.983 | 1.207 (0.782–1.862) | 0.395 |
Total chemotherpy (cycles)a | 0.935 (0.577–1.515) | 0.784 | 0.845 (0.631–1.130) | 0.256 | 0.919 (0.660–1.280) | 0.618 |
Response to NeoCT(CR/PR/SD) | 0.856 (0.092–7.936) | 0.891 | 0.510 (0.139–1.878) | 0.312 | 0.503 (0.120–2.105) | 0.347 |
Short-term treatment responseb(CR/PR) | 1.535 (0.533–4.425) | 0.427 | 1.260 (0.661–2.402) | 0.483 | 1.208 (0.583–2.503) | 0.611 |
MC | 0.037 (0.000–15.944) | 0.287 | 0.256 (0.062–1.067) | 0.061 | 0.168 (0.023–1.240) | 0.080 |